Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some mechanistic and safety-related statements are only partially supported or oversimplified, and multiple non-label business/market claims are included with no label support. Additionally, contraindications and pregnancy labeling are not assessable from the provided claims.
Category Scores
Accurate Statements
Lexapro is an antidepressant medication.
Supported by Indications and Usage/clinical pharmacology description (Sections 1, 12).
Lexapro belongs to the class of selective serotonin reuptake inhibitors (SSRIs).
Supported (Sections 11, 12.1).
Escitalopram is the generic name for Lexapro.
Supported (Section 11).
Escitalopram can alleviate symptoms associated with depression.
Supported by indication for major depressive disorder (Section 1).
Escitalopram can alleviate symptoms associated with anxiety disorders.
Supported by indication for generalized anxiety disorder (Section 1).
Lexapro is the brand name for escitalopram in the United States.
Supported (Sections 11, 17).
Common side effects of Lexapro include nausea.
Supported (Section 6.1).
Common side effects of Lexapro include insomnia.
Supported (Section 6.1).
Common side effects of Lexapro include ejaculation disorder.
Supported (Section 6.1).
Common side effects of Lexapro include fatigue.
Supported (Section 6.1).
Common side effects of Lexapro include increased sweating.
Supported (Section 6.1).
Lexapro is an SSRI.
Supported (Sections 11, 12.1).
As with all SSRIs, Lexapro carries a risk of suicidal thoughts and behaviors.
Partially supported by boxed warning language (Sections WARNING: SUICIDAL THOUGHTS AND BEHAVIORS; 5.1).
Lexapro can cause serotonin syndrome.
Supported (Section 5.2).
Serotonin syndrome can be potentially life-threatening.
Supported (Section 5.2).
Serotonin syndrome risk with Lexapro is especially when combined with other serotonergic drugs.
Supported (Sections 5.2, 7).
Patients should discuss pre-existing conditions or other medications with their doctor before starting Lexapro.
Partially supported (Sections 4, 5.2, 17) but not stated in that exact wording.
Unsupported Statements
Lexapro is widely prescribed.
Not supported by the provided prescribing information sections.
Lexapro is considered common.
Not supported by the provided prescribing information sections.
Escitalopram increases serotonin levels in the brain.
Only partially supported; label supports serotonergic activity/inhibition of serotonin reuptake, not an explicit claim about increasing serotonin levels in the brain (Sections 12.1, 5.2).
Escitalopram was first approved by the U.S. Food and Drug Administration (FDA) in 2002.
Not supported by the provided prescribing information sections.
Cipralex is the brand name for escitalopram in many other countries, including Canada and Europe.
Not supported by the provided prescribing information sections.
Lexapro and Cipralex are the same medication (same drug).
Not supported by the provided prescribing information sections.
Patent protection for brand-name Lexapro has expired.
Not supported by the provided prescribing information sections.
The expiration of patent protection for brand-name Lexapro allows for availability of generic versions.
Not supported by the provided prescribing information sections.
Generic escitalopram is available.
Not supported by the provided prescribing information sections.
Generic escitalopram is considered therapeutically equivalent to brand-name Lexapro.
Not supported by the provided prescribing information sections.
Generic escitalopram is expected to have the same effect and safety profile as brand-name Lexapro.
Not supported by the provided prescribing information sections.
Fluoxetine (Prozac), sertraline (Zoloft), and citalopram (Celexa) are other SSRIs.
Not supported by the provided prescribing information sections.
Individual responses and side effect profiles can vary among SSRIs.
Not supported by the provided prescribing information sections.
Healthcare providers may try different SSRIs to find the most effective option for a patient.
Not supported by the provided prescribing information sections.
Brand-name Lexapro is generally more expensive than its generic equivalent.
Not supported by the provided prescribing information sections.
The cost of Lexapro varies.
Not supported by the provided prescribing information sections.
The price of Lexapro is influenced by factors such as insurance coverage, pharmacy, and dosage.
Not supported by the provided prescribing information sections.
Contradictions
Important Omissions
Contraindications content (e.g., MAOI-related contraindications, pimozide contraindication, hypersensitivity) was not provided in the extracted claims, so label compliance for contraindications cannot be assessed.
Importance:
Moderate
Pregnancy and lactation labeling was not provided in the extracted claims, so compliance for pregnancy/lactation risk statements cannot be assessed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related statements are only partially supported (boxed warning scope; mechanism wording), and critical label sections (contraindications and pregnancy) are not assessable from the provided extracted claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple extracted claims are unsupported by the provided label text, and key boxed-warning scope statements and mechanistic wording are only partially supported. Contraindications and pregnancy labeling were not assessable.
Suggested Improvement
Limit claims to specific labeled indications, labeled safety warnings/precautions wording and scope (especially boxed warning context), labeled adverse reaction examples, and labeled pharmacology language. Exclude non-label market/patent/generic availability assertions unless explicitly present in the label.